Abstract B072: Phase Ib trial of the RNActive cancer vaccine BI 1361849 (CV9202) and local radiotherapy in patients with stage IV non-small cell lung cancer (NSCLC) with disease control after first-line chemotherapy or during therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: Updated clinical results and immune responses

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Stage Iv ◽

Clinical Results ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

Line Chemotherapy

Maintenance Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor after First-Line Chemotherapy in Mutation-Positive Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1097/jto.0000000000000597 ◽

2015 ◽

Vol 10 (8) ◽

pp. e81-e82

Author(s):

Young Hak Kim ◽

Michiaki Mishima

Keyword(s):

Lung Cancer ◽

Maintenance Treatment ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

Line Chemotherapy

Olmutinib in T790M‐positive non–small cell lung cancer after failure of first‐line epidermal growth factor receptor‐tyrosine kinase inhibitor therapy: A global, phase 2 study

Cancer ◽

10.1002/cncr.33385 ◽

2021 ◽

Author(s):

Keunchil Park ◽

Pasi A. Jӓnne ◽

Dong‐Wan Kim ◽

Ji‐Youn Han ◽

Ming‐Fang Wu ◽

...

Keyword(s):

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Tyrosine Kinase Inhibitor Therapy ◽

Phase 2 Study ◽

Epidermal Growth

Do We Really Need Another Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in First-Line Treatment for Patients With Non–Small-Cell Lung Cancer andEGFRMutations?

Journal of Clinical Oncology ◽

10.1200/jco.2013.52.8794 ◽

2014 ◽

Vol 32 (8) ◽

pp. 859-863 ◽

Cited By ~ 2

Author(s):

Eva R. Haspinger ◽

Marina Chiara Garassino ◽

Valter Torri ◽

Michela Cinquini ◽

Filippo De Braud ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis

Targeted Oncology ◽

10.1007/s11523-015-0373-x ◽

2015 ◽

Vol 11 (1) ◽

pp. 41-47 ◽

Cited By ~ 9

Author(s):

Gaetan Des Guetz ◽

Thierry Landre ◽

Bernard Uzzan ◽

Kader Chouahnia ◽

Patrick Nicolas ◽

...

Keyword(s):

Lung Cancer ◽

Survival Benefit ◽

Kinase Inhibitor ◽

Meta Analysis ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth

Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials

International Journal of Cancer ◽

10.1002/ijc.27396 ◽

2012 ◽

Vol 131 (5) ◽

pp. E822-E829 ◽

Cited By ~ 78

Author(s):

Guanghui Gao ◽

Shengxiang Ren ◽

Aiwu Li ◽

Jianfang Xu ◽

Qinghua Xu ◽

...

Keyword(s):

Kinase Inhibitor ◽

Meta Analysis ◽

Growth Factor Receptor ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Randomized Controlled ◽

Tyrosine Kinase Inhibitor Therapy ◽

Epidermal Growth

Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation

Lung Cancer ◽

10.1016/j.lungcan.2018.12.007 ◽

2019 ◽

Vol 128 ◽

pp. 6-12 ◽

Cited By ~ 5

Author(s):

Xiangtao Yan ◽

Huijuan Wang ◽

Peng Li ◽

Guowei Zhang ◽

Mina Zhang ◽

...

Keyword(s):

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

Egfr Tki ◽

Review of clinical benefits and cost effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) as first line treatment for patients with advanced non-small cell lung cancer (NSCLC)

10.5353/th_b4693532 ◽

2011 ◽

Author(s):

Ho-ying Choi

Keyword(s):

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Clinical Benefits ◽

Epidermal Growth ◽

Egfr Tki ◽

Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations

Cancer Research and Treatment ◽

10.4143/crt.2014.244 ◽

2015 ◽

Vol 47 (4) ◽

pp. 630-637 ◽

Cited By ~ 8

Author(s):

Sehhoon Park ◽

Bhumsuk Keam ◽

Se Hyun Kim ◽

Ki Hwan Kim ◽

Yu Jung Kim ◽

...

Keyword(s):

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Egfr Tyrosine Kinase Inhibitor ◽

Lung Cancer Patients ◽

Epidermal Growth ◽

Line Chemotherapy ◽

Platinum Doublet

Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis

Anticancer Research ◽

10.21873/anticanres.15331 ◽

2021 ◽

Vol 41 (10) ◽

pp. 5137-5145

Author(s):

SHO MITSUYA ◽

KENJIRO TSURUOKA ◽

KIYOE KANAOKA ◽

TOMOYA FUNAMOTO ◽

HIROYUKI TSUJI ◽

...

Keyword(s):

Kinase Inhibitors ◽

Growth Factor Receptor ◽

Small Cell ◽

Third Generation ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

Receptor Tyrosine Kinase Inhibitors ◽

Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases

Current Medical Science ◽

10.1007/s11596-018-1984-0 ◽

2018 ◽

Vol 38 (6) ◽

pp. 1062-1068 ◽

Cited By ~ 4

Author(s):

Shao-bo Ke ◽

Hu Qiu ◽

Jia-mei Chen ◽

Wei Shi ◽

Yong-shun Chen

Keyword(s):

Epidermal Growth Factor Receptor ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Whole Brain Radiotherapy ◽

First Line ◽

Brain Radiotherapy ◽

Epidermal Growth ◽

Egfr Tki